Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Acalabrutinib in patients with CLL and MCL undergoing alloSCT

Wojciech Jurczak • 11 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Acalabrutinib CAR-T

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, comments on the administration of acalabrutinib after allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Prof. Jurczak also comments on how the rapid advances in CAR-T cell therapies may impact this. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Wojciech Jurczak

1:35
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak • 10 Jun 2023
3:01
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL
Wojciech Jurczak • 10 Jun 2023
1:49
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak • 10 Jun 2023
1:05
Updates on tafasitamab for the treatment of DLBCL
Wojciech Jurczak • 11 Jun 2022

Related Videos

6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
1:56
Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
Dima El-Sharkawi • 28 Apr 2024
1:17
Using an AI model to quantify under-utilization of alloSCT for AML in the UK
Thomas Coats • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals